TLX101-Px (Pixlumi®) MAA Accepted in Europe

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Telix-Pharmaceuticals

More Like This

PR Newswire associated0

Telix Submits NDA for TLX101-CDx (Pixclara®) Brain Cancer Imaging Agent

PR Newswire associated0

Illuccix® Receives European Approval

PR Newswire associated0

IPAX-1 Study of TLX101 Investigational Glioblastoma Therapy Published in Neuro-Oncology Advances

PR Newswire associated0

IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate

PR Newswire associated0

Illuccix® Approved in the United Kingdom

PR Newswire associated0

Telix Featured in 13 Abstracts at the Annual Congress of the European Association of Nuclear Medicine (EANM)

PR Newswire associated0

Telix's Illuccix PSMA-PET Imaging Agent Approved in France

PR Newswire associated0

First Patient Dosed in European Named Patient (Early Access) Program for TLX250-CDx, Telix's Kidney Cancer Imaging Agent